CD8A and neoplasm: These two classes of novel anticancer agents work synergistically to exert cytotoxicity to cancer cells, eliminate immunosuppressive cells (including MDSC, TAM, Treg and exhausted CD8+ T cells), and elicit more potent and sustained systemic anti-tumour immunity, thus achieving better therapeutic efficacy.